Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of Endpoints in Phase III Randomized Controlled Trials for Hematopoietic Stem Cell Transplantation Over the Last 15 Years: A Systematic Review.
Shahzad M, Khalid MF, Amin MK, Ammad-Ud-Din M, Ilyas U, Mushtaq AH, Butt A, Anwar I, Chaudhary SG, Ahmed N, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: chaudhary sg. Hematol Oncol Stem Cell Ther. 2024 Mar 22;17(2):88-94. doi: 10.56875/2589-0646.1118. Hematol Oncol Stem Cell Ther. 2024. PMID: 38560970 Free article.
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis.
Shahzad M, Iqbal Q, Tariq E, Ammad-Ud-Din M, Butt A, Mushtaq AH, Ali F, Chaudhary SG, Anwar I, Gonzalez-Lugo JD, Abdelhakim H, Ahmed N, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: chaudhary sg. Crit Rev Oncol Hematol. 2024 Apr;196:104310. doi: 10.1016/j.critrevonc.2024.104310. Epub 2024 Feb 27. Crit Rev Oncol Hematol. 2024. PMID: 38423375 Free article. Review.
Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation.
Al-Ramahi JS, Shahzad M, Nguyen A, Li K, Amin MK, Ahmed N, Lutfi F, DeJarnette S, Chaudhary SG, Bansal R, Abdelhakim H, Shune L, Abdallah AO, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Al-Ramahi JS, et al. Among authors: chaudhary sg. Bone Marrow Transplant. 2024 Jan;59(1):134-137. doi: 10.1038/s41409-023-02125-x. Epub 2023 Oct 13. Bone Marrow Transplant. 2024. PMID: 37833526 No abstract available.
Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients.
Al-Ramahi JS, Shahzad M, Li K, DeJarnette S, Chaudhary SG, Lutfi F, Ahmed N, Balusu R, Bansal R, Abdelhakim H, Shune L, Singh AK, Abhyankar SH, McGuirk JP, Mushtaq MU. Al-Ramahi JS, et al. Among authors: chaudhary sg. Leuk Lymphoma. 2023 Dec;64(12):1981-1991. doi: 10.1080/10428194.2023.2243355. Epub 2023 Aug 13. Leuk Lymphoma. 2023. PMID: 37574842
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, Faisal MS, Tariq E, Ali F, Butt A, Anwar I, Chaudhary SG, Lutfi F, Ahmed N, Singh AK, Hematti P, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: chaudhary sg. Front Immunol. 2023 Apr 24;14:1152457. doi: 10.3389/fimmu.2023.1152457. eCollection 2023. Front Immunol. 2023. PMID: 37168849 Free PMC article. Review.
Outcomes of Tyrosine Kinase Inhibitors Maintenance Therapy with or without Allogeneic Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission: A Systematic Review and Meta-Analysis.
Shahzad M, Hussain A, Tariq E, Anwar I, Faisal MS, Syed L, Karam A, Chaudhary SG, Ahmed N, Bansal R, Khurana S, Singh AK, Byrd KP, Hematti P, Abhyankar SH, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: chaudhary sg. Clin Lymphoma Myeloma Leuk. 2023 Mar;23(3):178-187. doi: 10.1016/j.clml.2023.01.002. Epub 2023 Jan 12. Clin Lymphoma Myeloma Leuk. 2023. PMID: 36682989 Review.
Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review.
Shahzad M, Chaudhary SG, Tariq E, Mushtaq AH, Anwar I, Ahmed N, Bansal R, Lutfi F, Balusu R, Abdelhakim H, Yacoub A, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: chaudhary sg. Leuk Lymphoma. 2023 Feb;64(2):273-282. doi: 10.1080/10428194.2022.2136947. Epub 2022 Oct 25. Leuk Lymphoma. 2023. PMID: 36282773
Outcomes with mismatched unrelated donor allogeneic hematopoietic stem cell transplantation in adults: A systematic review and meta-analysis.
Mushtaq MU, Shahzad M, Tariq E, Iqbal Q, Chaudhary SG, Zafar MU, Anwar I, Ahmed N, Bansal R, Singh AK, Abhyankar SH, Callander NS, Hematti P, McGuirk JP. Mushtaq MU, et al. Among authors: chaudhary sg. Front Oncol. 2022 Oct 6;12:1005042. doi: 10.3389/fonc.2022.1005042. eCollection 2022. Front Oncol. 2022. PMID: 36276084 Free PMC article.
Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Mushtaq MU, Shahzad M, Shah AY, Chaudhary SG, Zafar MU, Anwar I, Neupane K, Khalid A, Ahmed N, Bansal R, Balusu R, Singh AK, Abhyankar SH, Callander NS, Hematti P, McGuirk JP. Mushtaq MU, et al. Among authors: chaudhary sg. Front Immunol. 2022 Oct 3;13:1005031. doi: 10.3389/fimmu.2022.1005031. eCollection 2022. Front Immunol. 2022. PMID: 36263054 Free PMC article.
Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Tariq E, Chaudhary SG, Anwar I, Iqbal Q, Fatima H, Abdelhakim H, Ahmed N, Balusu R, Hematti P, Singh AK, McGuirk JP, Mushtaq MU. Shahzad M, et al. Among authors: chaudhary sg. Leuk Lymphoma. 2022 Dec;63(14):3409-3417. doi: 10.1080/10428194.2022.2123228. Epub 2022 Sep 15. Leuk Lymphoma. 2022. PMID: 36107118
20 results